DP
SMMT icon

Diadema Partners’s Summit Therapeutics SMMT Stock Holding History

Diadema Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-932
Closed -$22.6K – 162
2025
Q2 		$19.8K Buy
+932
New +$21.3K 0.01% 93

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Diadema Partners's SMMT Position: Q3 2025 in Review

Diadema Partners sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 932 shares — an estimated $22.6K sold.

Diadema Partners first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $19.8K in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Diadema Partners reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Diadema Partners sold 932 Summit Therapeutics shares in Q3 2025, an estimated $22.6K.
  • Diadema Partners first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
  • Diadema Partners's Summit Therapeutics position peaked at $19.8K in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.